Background: Systemic hypertension is alleged to increase the risk of glaucoma. As clinically Primary Open angle Glaucoma (POAG) is diagnosed only after approximately 40% of ganglion cell loss has occurred, therefore this study was commenced with an aim to determine the prevalence of pre-perimetric glaucomatous damage and its association with systemic hypertension using optical coherence tomography (OCT).
Materials And Methods: A total of 680 study participants were enrolled in this cross-sectional study. Among them 340 patients were of systemic hypertension (Group 1) and 340 patients without hypertension (Group 2). All patients underwent detailed history, ocular and systemic examination including slit lamp examination, fundus examination by +90 D lens, Humphrey field analyser for field charting and OCT for nerve fiber analysis. For glaucomatous nerve damage.
Results: Group 1 and Group 2 had Male: Female ratio of 1:8 and 1:9, respectively ( = 0.809). Maximum participants 48.8% and 54.4% in Group 1 and Group 2, respectively, were in age group 50-59 years. Statistically significant difference was seen in the percentage of pre-perimetric glaucomatous patients between the two groups ( < 0.001). On OCT analysis between pre-perimetric glaucomatous eyes and healthy eyes significant difference in thickness was seen in temporal inner macula, inferior outer macula, temporal outer macula, superior outer macula and nasal outer macula. Significant difference in volume was seen for inferior temporal and nasal outer macula (P < 0.001).
Conclusion: In hypertensives, glaucomatous optic nerve damage starts much earlier before the obvious clinical signs of POAG appear, as compared to normotensive individuals.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731015 | PMC |
http://dx.doi.org/10.4103/jfmpc.jfmpc_2288_21 | DOI Listing |
Invest Ophthalmol Vis Sci
January 2025
Institute for Applied Mathematics, University of Bonn, Bonn, Germany.
Purpose: To quantify outer retina structural changes and define novel biomarkers of inherited retinal degeneration associated with biallelic mutations in RPE65 (RPE65-IRD) in patients before and after subretinal gene augmentation therapy with voretigene neparvovec (Luxturna).
Methods: Application of advanced deep learning for automated retinal layer segmentation, specifically tailored for RPE65-IRD. Quantification of five novel biomarkers for the ellipsoid zone (EZ): thickness, granularity, reflectivity, and intensity.
J Vitreoretin Dis
December 2024
Octane Imaging Lab, Toronto, ON, Canada.
J Vitreoretin Dis
December 2024
Retina Department, Fundación Hospital de Nuestra Señora de La Luz, Mexico City, Mexico.
Invest Ophthalmol Vis Sci
December 2024
Department of Translational Biomedicine Neuroscience, University of Bari "Aldo Moro," Bari, Italy.
Purpose: The purpose of this study was o examine the optical coherence tomographic (OCT) characteristics of hyper-reflective foci (HRF) in patients with neovascular age-related macular degeneration (nAMD) and to assess the potential of HRF as a predictive factor for the development of macular atrophy following anti-vascular endothelial growth factor (anti-VEGF) therapy.
Methods: This was a retrospective analysis of 61 treatment-naïve eyes diagnosed with exudative AMD and type 1 macular neovascularization (MNV). The HRF was identified in the inner retina and outer retina layers, and the treatment response of HRF was documented.
Am J Ophthalmol Case Rep
December 2024
Royal Hobart Hospital, Uveitis Clinic, Hobart, Tasmania, Australia.
Purpose: To describe the clinical and imaging characteristics of the acute progressive phase of a recently proposed clinical entity, Multizonal Outer Retinopathy and Retinal Pigment Epitheliopathy (MORR), a variant of Acute Zonal Occult Outer Retinopathy (AZOOR).
Methods: Single observational case report.
Results: We present the case of a 49-year-old myopic female with progressive outer retinopathy most consistent with a diagnosis of MORR.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!